

# Ivo N Van Schaik

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6767177/publications.pdf>

Version: 2024-02-01

40  
papers

1,218  
citations

567281

15  
h-index

377865

34  
g-index

40  
all docs

40  
docs citations

40  
times ranked

1402  
citing authors

#	ARTICLE	IF	CITATIONS
1	Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Neurology</i> , The, 2018, 17, 35-46.	10.2	193
2	Pulsed high-dose dexamethasone versus standard prednisolone treatment for chronic inflammatory demyelinating polyradiculoneuropathy (PREDICT study): a double-blind, randomised, controlled trial. <i>Lancet Neurology</i> , The, 2010, 9, 245-253.	10.2	170
3	Impact of ICU-acquired weakness on post-ICU physical functioning: a follow-up study. <i>Critical Care</i> , 2015, 19, 196.	5.8	137
4	Treatments for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): an overview of systematic reviews. <i>The Cochrane Library</i> , 2017, 2017, CD010369.	2.8	88
5	Is Dosing of Therapeutic Immunoglobulins Optimal? A Review of a Three-Decade Long Debate in Europe. <i>Frontiers in Immunology</i> , 2014, 5, 629.	4.8	76
6	Serum neurofilament light chain in chronic inflammatory demyelinating polyneuropathy. <i>Journal of the Peripheral Nervous System</i> , 2019, 24, 187-194.	3.1	59
7	Diagnostic accuracy of quantitative neuromuscular ultrasound for the diagnosis of intensive care unit-acquired weakness: a cross-sectional observational study. <i>Annals of Intensive Care</i> , 2017, 7, 40.	4.6	54
8	Diagnostic accuracy of MRI and ultrasound in chronic immune-mediated neuropathies. <i>Neurology</i> , 2020, 94, e62-e74.	1.1	51
9	Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy: a systematic review. <i>Lancet Neurology</i> , The, 2002, 1, 491-498.	10.2	43
10	Long-term safety and efficacy of subcutaneous immunoglobulin IgPro20 in CIDP. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2019, 6, e590.	6.0	37
11	Early Prediction of Intensive Care Unit-“Acquired Weakness Using Easily Available Parameters: A Prospective Observational Study. <i>PLoS ONE</i> , 2014, 9, e111259.	2.5	32
12	Muscle and nerve inflammation in intensive care unit-acquired weakness: A systematic translational review. <i>Journal of the Neurological Sciences</i> , 2014, 345, 15-25.	0.6	25
13	Intravenous immunoglobulins as first-line treatment in idiopathic inflammatory myopathies: a pilot study. <i>Rheumatology</i> , 2021, 60, 1784-1792.	1.9	25
14	Development and clinical consequences of white matter lesions in Fabry disease: a systematic review. <i>Molecular Genetics and Metabolism</i> , 2018, 125, 205-216.	1.1	23
15	Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (The PATH Study): study protocol for a randomized controlled trial. <i>Trials</i> , 2016, 17, 345.	1.6	21
16	Depressive symptoms in Fabry disease: the importance of coping, subjective health perception and pain. <i>Orphanet Journal of Rare Diseases</i> , 2020, 15, 28.	2.7	19
17	Efficacy and safety of IVIG in CIDP: Combined data of the PRIMA and PATH studies. <i>Journal of the Peripheral Nervous System</i> , 2019, 24, 48-55.	3.1	17
18	Withdrawal of intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy. <i>Brain</i> , 2022, 145, 1641-1652.	7.6	16

#	ARTICLE	IF	CITATIONS
19	Elevated leukocyte count in cerebrospinal fluid of patients with chronic inflammatory demyelinating polyneuropathy. <i>Journal of the Peripheral Nervous System</i> , 2018, 23, 49-54.	3.1	15
20	Drug-induced cutaneous lupus erythematosus after immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy: a case series. <i>Journal of the Peripheral Nervous System</i> , 2017, 22, 213-218.	3.1	13
21	Restabilization treatment after intravenous immunoglobulin withdrawal in chronic inflammatory demyelinating polyneuropathy: Results from the pre-randomization phase of the Polyneuropathy And Treatment with Hizentra study. <i>Journal of the Peripheral Nervous System</i> , 2019, 24, 72-79.	3.1	13
22	Association between i.v. thrombolysis volume and door-to-needle times in acute ischemic stroke. <i>Journal of Neurology</i> , 2016, 263, 807-813.	3.6	10
23	Intravenous immunoglobulins in patients with clinically suspected chronic immune-mediated neuropathy. <i>Journal of the Neurological Sciences</i> , 2019, 397, 141-145.	0.6	10
24	Assessment of intensive care unit-acquired weakness in young and old mice: An E. coli septic peritonitis model. <i>Muscle and Nerve</i> , 2016, 53, 127-133.	2.2	8
25	Cognitive functioning and depressive symptoms in Fabry disease: A follow-up study. <i>Journal of Inherited Metabolic Disease</i> , 2020, 43, 1070-1081.	3.6	8
26	The Mini Mental State Examination does not accurately screen for objective cognitive impairment in Fabry Disease. <i>JIMD Reports</i> , 2019, 48, 53-59.	1.5	7
27	What's new in chronic inflammatory demyelinating polyradiculoneuropathy in 2007-2008?. <i>Journal of the Peripheral Nervous System</i> , 2008, 13, 258-260.	3.1	6
28	First-line treatment for CIDP: a new piece of the puzzle. <i>Lancet Neurology</i> , The, 2012, 11, 478-479.	10.2	6
29	In Patients with an Î±-Galactosidase A Variant, Small Nerve Fibre Assessment Cannot Confirm a Diagnosis of Fabry Disease. <i>JIMD Reports</i> , 2015, 28, 95-103.	1.5	6
30	Immunoglobulin for multifocal motor neuropathy. <i>The Cochrane Library</i> , 2022, 2022, CD004429.	2.8	6
31	Ultrasound and MR muscle imaging in new onset idiopathic inflammatory myopathies at diagnosis and after treatment: a comparative pilot study. <i>Rheumatology</i> , 2022, 62, 300-309.	1.9	6
32	Immunotherapy of chronic inflammatory demyelinating polyradiculoneuropathy. <i>Expert Opinion on Biological Therapy</i> , 2008, 8, 643-655.	3.1	5
33	Muscle weakness in a S. pneumoniae sepsis mouse model. <i>Annals of Translational Medicine</i> , 2019, 7, 9-9.	1.7	4
34	Analysis of relapse by inflammatory Rasch-built overall disability scale status in the <scp>PATH</scp> study of subcutaneous immunoglobulin in chronic inflammatory demyelinating polyneuropathy. <i>Journal of the Peripheral Nervous System</i> , 2022, 27, 159-165.	3.1	3
35	Pharmacometric analysis linking immunoglobulin exposure to clinical efficacy outcomes in chronic inflammatory demyelinating polyneuropathy. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2021, 10, 839-850.	2.5	2
36	No association between systemic complement activation and intensive care unit-acquired weakness. <i>Annals of Translational Medicine</i> , 2018, 6, 115-115.	1.7	2

#	ARTICLE	IF	CITATIONS
37	Optimisation of Diagnostic Accuracy in idiopathic inflammatory myopathies (ADAPT study): a protocol for a prospective diagnostic accuracy study of multimodality testing in patients suspected of a treatable idiopathic inflammatory myopathy. <i>BMJ Open</i> , 2021, 11, e053594.	1.9	1
38	Assessment of disability in idiopathic inflammatory myopathy: a call for linearity. <i>Rheumatology</i> , 2022, 61, 3420-3426.	1.9	1
39	Intravenous versus subcutaneous immunoglobulin – Authors' reply. <i>Lancet Neurology</i> , The, 2018, 17, 393-394.	10.2	0
40	Efficacy and safety of intravenous immunoglobulin (IVIg) IGPRO10 in chronic inflammatory demyelinating polyneuropathy (CIDP). <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018, 89, A19.2-A19.	1.9	0